Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
The CY 2027 PFS Final Rule (published November 4, 2026) makes no structural changes to MSSP's core financial architecture — the BASIC/ENHANCED track system, shared savings rates, and benchmark methodology remain intact. What it does do is signal three durable design commitments that executives should read carefully.
First, CMS is permanently institutionalizing flat benchmarks for Medicare CQMs. For the CY 2027 performance period and all subsequent years, every measure in the Medicare CQMs collection type will be scored using flat benchmarks rather than historical benchmarks. CMS went further and applied this retroactively to three specific measures — Diabetes: Glycemic Status Assessment Greater Than 9% (Quality ID: 001), Screening for Depression and Follow-up Plan (Quality ID: 134), and Controlling High Blood Pressure (Quality ID: 236) — for the CY 2026 performance period as well. This is a material quality scoring concession. Flat benchmarks are systematically more achievable than historical benchmarks for ACOs that have already driven performance improvement into their populations, because historical benchmarks ratchet upward as national performance improves. ACOs using the Medicare CQMs collection type now face a permanently more favorable scoring environment — but only if they are structured to fully exploit it.
Second, CMS is creating a new Medicare eCQM collection type exclusively for MSSP ACOs beginning with CY 2027. The patient population for Medicare eCQMs is bounded to the ACO's assigned beneficiaries — not the full practice population — which aligns quality reporting directly with the financial accountability population. This is architecturally correct and closes a longstanding logical gap. However, ACOs that choose the Medicare eCQM collection type are explicitly ineligible for the Complex Organization Adjustment or the eCQM/MIPS CQM reporting incentive. That tradeoff must be modeled before selection.
Third, the MIPS CQMs collection type has been extended permanently (previously scheduled to sunset after CY 2026). This matters because it preserves ACO flexibility across three collection type options — eCQMs, Medicare CQMs, and MIPS CQMs — plus the new Medicare eCQMs pathway. ACOs with heterogeneous participant data infrastructure can maintain differentiated reporting strategies across participant groups rather than being forced into a single collection methodology.
The APP Plus quality measure set shrinks from 10 measures to 8 beginning CY 2027, with the removal of Initiation and Engagement of Substance Use Disorder Treatment (Quality ID: 305) and Adult Immunization Status (Quality ID: 493). Fewer required measures reduces reporting burden but narrows the quality performance differentiation ACOs can demonstrate — a tradeoff that disadvantages high-performing ACOs seeking to distinguish themselves for future contracting leverage.
MSSP remains the only permanent, statute-based ACO program available to Medicare FFS providers. That stability has concrete financial value that CMMI model participants do not enjoy. ACOs that achieve Qualifying APM Participant (QP) status receive a fee schedule update that grows 0.5% annually relative to non-QPs — a compounding advantage that grows in importance as the QP/non-QP divergence widens over multi-year periods.
The CY 2027 rule modifies QP and Partial QP determination methodology in a way that has direct revenue implications. QP and Partial QP determinations will now be applied at the TIN/NPI level rather than the NPI level alone. The practical effect: financial incentives flow only to TINs that are actively participating in an Advanced APM. For multi-TIN physician practices or health systems where clinicians bill under both participating and non-participating TINs, this change eliminates the prior benefit of MIPS exemption at non-participating TINs. ACOs whose participants have complex TIN structures should model the net QP threshold impact immediately — some participants who previously achieved QP exemption across all billing entities will now face MIPS participation requirements at specific TINs.
On the MIPS performance adjustment side, the maximum negative payment adjustment remains at -9% through the 2029 MIPS payment year (CY 2027 performance period). The performance threshold remains at 75 points through CY 2028. ACOs reporting via the APP whose underlying participants fall below 18.75 points face the full -9% adjustment — a hard floor that quantifies the downside of quality underperformance in dollar terms. For a physician generating $500,000 in Medicare Part B billings annually, the -9% floor represents a $45,000 negative payment adjustment. At scale across a 200-physician ACO, that exposure is $9 million annually. Quality infrastructure is not optional overhead — it is loss prevention.
Advance Investment Payments (AIP) and Prepaid Shared Savings (PSS) remain available as of this rule cycle. AIP targets new, low-revenue ACOs to fund infrastructure buildout before savings materialize. PSS targets experienced two-sided risk ACOs with demonstrated savings history and provides upfront capital against expected performance payments. Both programs address the fundamental cash flow problem in ACO participation: savings are reconciled annually, creating a 12–18 month lag between care delivery and payment receipt. Organizations without sufficient operating capital to absorb that lag cannot sustain meaningful investment in care management staff, analytics platforms, or population health programs. The PSS pathway is strategically underutilized by eligible ACOs.
The January 1, 2027 application cycle has already closed (Phase 1 Submission ran June 9–23, 2026; Final Dispositions were December 8, 2026; ACO Signing Event closed December 16, 2026). Organizations targeting a January 1, 2028 start date should initiate track selection analysis and ACO Participant List construction no later than Q1 2027.
Large, integrated health systems are structurally advantaged in MSSP because they can internalize the care management, data analytics, and attribution management functions that smaller organizations must purchase externally. The flat Medicare CQM benchmarks benefit any ACO that has already optimized performance on the core APP Plus measure set — which larger systems disproportionately have. The PSS program is effectively only accessible to systems with multi-year savings track records and two-sided risk experience, further concentrating capital access among incumbents.
Physician group-led ACOs and federally qualified health centers face the more challenging financial profile. They bear the fixed costs of ACO infrastructure — ACO-MS compliance, repayment mechanism establishment (escrow, letter of credit, or surety bond for BASIC Level C–E and ENHANCED track participants), quality reporting infrastructure, and care coordination staffing — against a beneficiary population that may be insufficient in scale to generate statistically credible savings calculations. The AIP pathway exists specifically to address this structural disadvantage but requires deliberate navigation of supplemental information and spend plan requirements.
Medicare Advantage plans face an asymmetric dynamic. As MSSP ACOs grow in sophistication and attributed beneficiary population management, the evidence base for ACO-MA alignment programs strengthens — but the two programs' incentive structures remain partially misaligned. MSSP ACOs are accountable for FFS expenditure benchmarks that MA enrollment erodes by removing attributed beneficiaries from the FFS pool. ACOs in markets with high and growing MA penetration face benchmark instability and attributed population shrinkage simultaneously.
The TIN/NPI-level QP determination change creates a new competitive disadvantage for large multi-specialty groups that have used NPI-level QP status to shield non-participating TINs from MIPS. Organizations that relied on that structural protection should conduct a TIN-by-TIN QP threshold analysis before the CY 2026 performance period data submission deadline (January–March 2027).
Physician perspective: The permanent extension of MIPS CQMs for ACO reporting, combined with the sunset of traditional MIPS after CY 2030, creates a coherent transition pathway for MSSP-participating physicians. Clinicians in MSSP ACOs reporting via the APP or APP Plus are exempt from the new MIPS core measure requirement that applies to traditional MIPS and MVP reporters — a meaningful administrative relief. The removal of the Security Risk Analysis measure from the Promoting Interoperability category (effective CY 2027) and the ONC Direct Review/ONC-ACB attestations (effective CY 2026) reduce annual compliance burden. The Electronic Prior Authorization measure is optional/bonus (10 bonus points) for CY 2027 before becoming mandatory in CY 2028 — a one-year runway to build CEHRT-based prior authorization workflows.
Health system perspective: The Medicare eCQM collection type creates a new data infrastructure requirement: ACOs must use eCQM specifications but report on assigned beneficiaries only, using a distinct submission identifier. Systems without mature population-level EHR reporting infrastructure will find this collection type operationally costly relative to continued Medicare CQM or MIPS CQM reporting. The tradeoff — forgoing the Complex Organization Adjustment and the eCQM/MIPS CQM reporting incentive — must be explicitly modeled. For systems with strong EHR infrastructure, the Medicare eCQM pathway may ultimately offer cleaner alignment between quality reporting and financial accountability populations.
Hospital perspective: Critical Access Hospitals billing under Method II and hospitals employing ACO professionals remain eligible ACO participants. The SNF 3-Day Rule Waiver — available only to ACOs in two-sided risk tracks — continues to offer a meaningful care coordination tool for reducing unnecessary inpatient admission days prior to SNF transitions. Hospitals participating in MSSP ACOs should track the SNF affiliate list management requirements carefully; the ACO-MS change request cycles have hard deadlines that cannot be extended.
Payer/MA plan perspective: MA plans operating in markets with dense MSSP ACO participation should monitor attributed beneficiary migration carefully. The 2026 ACO participation data (released February 4, 2026) and the pending 2027 cohort represent the most current signal of FFS population accountability coverage. MA plans designing ACO co-participation or preferred network arrangements with MSSP ACOs should ensure contractual structures account for the MSSP benchmark methodology's sensitivity to market penetration — high MA enrollment in an ACO's service area reduces the regional FFS expenditure pool against which the ACO's benchmark is calculated.
Analysis based on CY 2027 PFS Final Rule (published November 4, 2026) and current CMS MSSP program documentation. Application dates for a January 1, 2028 agreement start date have not yet been published as of this analysis.